MedTrace Logo

COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses

NCT04352959 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2021-02-11

No results posted yet for this study

Summary

Given the current lack of effective COVID-19 treatment, it is necessary to explore alternative methods to contain the spread of the infection, focusing in particular on its mode of transmission. The modes of person-to-person transmission of SARS-CoV-2 are direct transmission, such as sneezing, coughing, transmission through inhalation of small droplets, and transmission through contact, such as contact with nasal, oral and eye mucous membranes. SARS-CoV-2 can also be transmitted directly or indirectly through saliva. The use of antiviral mouthrinses may be used as adjunctive therapy.

Conditions

  • COVID19
  • Mouthwash
  • Saliva

Interventions

DEVICE

mouthrinse with bêta-cyclodextrin and citrox

3 daily mouthrinses for 7 days

DEVICE

mouthrinse without bêta-cyclodextrin and citrox

3 daily mouthrinses for 7 days

Sponsors & Collaborators

  • Hospices Civils de Lyon

    collaborator OTHER

  • Claude Bernard University

    lead OTHER

Principal Investigators

  • Florence Carrouel, Dr · University Claude Bernard Lyon 1

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-27
Primary Completion
2020-12-11
Completion
2020-12-11

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04352959 on ClinicalTrials.gov